{"id":74400,"date":"2020-03-27T15:45:33","date_gmt":"2020-03-27T14:45:33","guid":{"rendered":"https:\/\/www.cfmot.de\/sirolimus-api\/"},"modified":"2020-03-27T15:47:30","modified_gmt":"2020-03-27T14:47:30","slug":"sirolimus-api","status":"publish","type":"post","link":"https:\/\/www.cfmot.de\/en\/sirolimus-api\/","title":{"rendered":"Sirolimus API"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"74400\" class=\"elementor elementor-74400 elementor-74394\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-aa4d1ed elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"aa4d1ed\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-97314c0\" data-id=\"97314c0\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-038e407 elementor-widget elementor-widget-text-editor\" data-id=\"038e407\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><strong>Sirolimus \/ Rapamycin for facial angiofibromas<\/strong><\/p><p>A Sirolimus vaseline\u00ae 0.1% jelly produced by pharmacies according to an prescription shows success in the treatment of facial angiofibromas.<\/p><p>Facial angiofirbomas are a symptom of tuberous sclerosis (TSC also Pringle-Bourneville disease). Tuberous sclerosis is a multi-system disease. At least for the treatment of facial angiofibromas, a rapamycin vaseline\u00ae jelly helps!<\/p><p>TSC is caused by inactivating mutations on the TSC-1 or TSC2 gene. These two genes play an important role in the regulation of phosphoinostide-3-kinase (PI3K) and the inhibition of the enzyme mTOR.<\/p><p>A 0.05 or 0.1% Sirolimus valselin\u00ae jelly should be sufficient for a first therapy attempt.<\/p><p>Cfm Oskar Tropitzsch GmbH offers Sirolimus \/ Rapamycin as an EU API according to AMG \/ AMWHV in 5g packaging customary for pharmacies.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Sirolimus \/ Rapamycin for facial angiofibromas A Sirolimus vaseline\u00ae 0.1% jelly produced by pharmacies according to an prescription shows success in the treatment of facial angiofibromas. Facial angiofirbomas are a symptom of tuberous sclerosis (TSC also Pringle-Bourneville disease). Tuberous sclerosis is a multi-system disease. At least for the treatment of facial angiofibromas, a rapamycin vaseline\u00ae [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":74396,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[48,136,139],"tags":[],"class_list":["post-74400","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog-en-2","category-fermentation-products","category-pharmaceutical-products"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Sirolimus API - Cfm Oskar Tropitzsch GmbH<\/title>\n<meta name=\"description\" content=\"A Sirolimus vaseline\u00ae jelly 0.1% cream produced by pharmacies according to an prescription shows great success in the treatment of facial angiofibromas.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cfmot.de\/en\/sirolimus-api\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sirolimus API - Cfm Oskar Tropitzsch GmbH\" \/>\n<meta property=\"og:description\" content=\"A Sirolimus vaseline\u00ae jelly 0.1% cream produced by pharmacies according to an prescription shows great success in the treatment of facial angiofibromas.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cfmot.de\/en\/sirolimus-api\/\" \/>\n<meta property=\"og:site_name\" content=\"Cfm Oskar Tropitzsch GmbH\" \/>\n<meta property=\"article:published_time\" content=\"2020-03-27T14:45:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-03-27T14:47:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cfmot.de\/wp-content\/uploads\/2020\/03\/Pharmazeutische-Zeitung-Rapamycin-API.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Michael.Schaeffler\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Michael.Schaeffler\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.cfmot.de\\\/en\\\/sirolimus-api\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.cfmot.de\\\/en\\\/sirolimus-api\\\/\"},\"author\":{\"name\":\"Michael.Schaeffler\",\"@id\":\"https:\\\/\\\/www.cfmot.de\\\/en\\\/#\\\/schema\\\/person\\\/27be9490c258e644757e598549f606cc\"},\"headline\":\"Sirolimus API\",\"datePublished\":\"2020-03-27T14:45:33+00:00\",\"dateModified\":\"2020-03-27T14:47:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.cfmot.de\\\/en\\\/sirolimus-api\\\/\"},\"wordCount\":125,\"image\":{\"@id\":\"https:\\\/\\\/www.cfmot.de\\\/en\\\/sirolimus-api\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.cfmot.de\\\/wp-content\\\/uploads\\\/2020\\\/03\\\/Pharmazeutische-Zeitung-Rapamycin-API.jpg\",\"articleSection\":[\"Blog\",\"Fermentation Products\",\"Pharmaceutical Products\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.cfmot.de\\\/en\\\/sirolimus-api\\\/\",\"url\":\"https:\\\/\\\/www.cfmot.de\\\/en\\\/sirolimus-api\\\/\",\"name\":\"Sirolimus API - Cfm Oskar Tropitzsch GmbH\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.cfmot.de\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.cfmot.de\\\/en\\\/sirolimus-api\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.cfmot.de\\\/en\\\/sirolimus-api\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.cfmot.de\\\/wp-content\\\/uploads\\\/2020\\\/03\\\/Pharmazeutische-Zeitung-Rapamycin-API.jpg\",\"datePublished\":\"2020-03-27T14:45:33+00:00\",\"dateModified\":\"2020-03-27T14:47:30+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.cfmot.de\\\/en\\\/#\\\/schema\\\/person\\\/27be9490c258e644757e598549f606cc\"},\"description\":\"A Sirolimus vaseline\u00ae jelly 0.1% cream produced by pharmacies according to an prescription shows great success in the treatment of facial angiofibromas.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.cfmot.de\\\/en\\\/sirolimus-api\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.cfmot.de\\\/en\\\/sirolimus-api\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.cfmot.de\\\/en\\\/sirolimus-api\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.cfmot.de\\\/wp-content\\\/uploads\\\/2020\\\/03\\\/Pharmazeutische-Zeitung-Rapamycin-API.jpg\",\"contentUrl\":\"https:\\\/\\\/www.cfmot.de\\\/wp-content\\\/uploads\\\/2020\\\/03\\\/Pharmazeutische-Zeitung-Rapamycin-API.jpg\",\"width\":1080,\"height\":1080,\"caption\":\"Rapamycin zur Behandlung f\u00fcr Gesichts Angiofibrome\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.cfmot.de\\\/en\\\/sirolimus-api\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.cfmot.de\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sirolimus API\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.cfmot.de\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.cfmot.de\\\/en\\\/\",\"name\":\"Cfm Oskar Tropitzsch GmbH\",\"description\":\"Chemikalien, Feinchemikalien, Metallverbindungen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.cfmot.de\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.cfmot.de\\\/en\\\/#\\\/schema\\\/person\\\/27be9490c258e644757e598549f606cc\",\"name\":\"Michael.Schaeffler\",\"url\":\"https:\\\/\\\/www.cfmot.de\\\/en\\\/author\\\/michael-schaeffler\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sirolimus API - Cfm Oskar Tropitzsch GmbH","description":"A Sirolimus vaseline\u00ae jelly 0.1% cream produced by pharmacies according to an prescription shows great success in the treatment of facial angiofibromas.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cfmot.de\/en\/sirolimus-api\/","og_locale":"en_US","og_type":"article","og_title":"Sirolimus API - Cfm Oskar Tropitzsch GmbH","og_description":"A Sirolimus vaseline\u00ae jelly 0.1% cream produced by pharmacies according to an prescription shows great success in the treatment of facial angiofibromas.","og_url":"https:\/\/www.cfmot.de\/en\/sirolimus-api\/","og_site_name":"Cfm Oskar Tropitzsch GmbH","article_published_time":"2020-03-27T14:45:33+00:00","article_modified_time":"2020-03-27T14:47:30+00:00","og_image":[{"width":1080,"height":1080,"url":"https:\/\/www.cfmot.de\/wp-content\/uploads\/2020\/03\/Pharmazeutische-Zeitung-Rapamycin-API.jpg","type":"image\/jpeg"}],"author":"Michael.Schaeffler","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Michael.Schaeffler","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.cfmot.de\/en\/sirolimus-api\/#article","isPartOf":{"@id":"https:\/\/www.cfmot.de\/en\/sirolimus-api\/"},"author":{"name":"Michael.Schaeffler","@id":"https:\/\/www.cfmot.de\/en\/#\/schema\/person\/27be9490c258e644757e598549f606cc"},"headline":"Sirolimus API","datePublished":"2020-03-27T14:45:33+00:00","dateModified":"2020-03-27T14:47:30+00:00","mainEntityOfPage":{"@id":"https:\/\/www.cfmot.de\/en\/sirolimus-api\/"},"wordCount":125,"image":{"@id":"https:\/\/www.cfmot.de\/en\/sirolimus-api\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cfmot.de\/wp-content\/uploads\/2020\/03\/Pharmazeutische-Zeitung-Rapamycin-API.jpg","articleSection":["Blog","Fermentation Products","Pharmaceutical Products"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.cfmot.de\/en\/sirolimus-api\/","url":"https:\/\/www.cfmot.de\/en\/sirolimus-api\/","name":"Sirolimus API - Cfm Oskar Tropitzsch GmbH","isPartOf":{"@id":"https:\/\/www.cfmot.de\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cfmot.de\/en\/sirolimus-api\/#primaryimage"},"image":{"@id":"https:\/\/www.cfmot.de\/en\/sirolimus-api\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cfmot.de\/wp-content\/uploads\/2020\/03\/Pharmazeutische-Zeitung-Rapamycin-API.jpg","datePublished":"2020-03-27T14:45:33+00:00","dateModified":"2020-03-27T14:47:30+00:00","author":{"@id":"https:\/\/www.cfmot.de\/en\/#\/schema\/person\/27be9490c258e644757e598549f606cc"},"description":"A Sirolimus vaseline\u00ae jelly 0.1% cream produced by pharmacies according to an prescription shows great success in the treatment of facial angiofibromas.","breadcrumb":{"@id":"https:\/\/www.cfmot.de\/en\/sirolimus-api\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cfmot.de\/en\/sirolimus-api\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.cfmot.de\/en\/sirolimus-api\/#primaryimage","url":"https:\/\/www.cfmot.de\/wp-content\/uploads\/2020\/03\/Pharmazeutische-Zeitung-Rapamycin-API.jpg","contentUrl":"https:\/\/www.cfmot.de\/wp-content\/uploads\/2020\/03\/Pharmazeutische-Zeitung-Rapamycin-API.jpg","width":1080,"height":1080,"caption":"Rapamycin zur Behandlung f\u00fcr Gesichts Angiofibrome"},{"@type":"BreadcrumbList","@id":"https:\/\/www.cfmot.de\/en\/sirolimus-api\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.cfmot.de\/en\/"},{"@type":"ListItem","position":2,"name":"Sirolimus API"}]},{"@type":"WebSite","@id":"https:\/\/www.cfmot.de\/en\/#website","url":"https:\/\/www.cfmot.de\/en\/","name":"Cfm Oskar Tropitzsch GmbH","description":"Chemikalien, Feinchemikalien, Metallverbindungen","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cfmot.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.cfmot.de\/en\/#\/schema\/person\/27be9490c258e644757e598549f606cc","name":"Michael.Schaeffler","url":"https:\/\/www.cfmot.de\/en\/author\/michael-schaeffler\/"}]}},"_links":{"self":[{"href":"https:\/\/www.cfmot.de\/en\/wp-json\/wp\/v2\/posts\/74400","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cfmot.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cfmot.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cfmot.de\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cfmot.de\/en\/wp-json\/wp\/v2\/comments?post=74400"}],"version-history":[{"count":3,"href":"https:\/\/www.cfmot.de\/en\/wp-json\/wp\/v2\/posts\/74400\/revisions"}],"predecessor-version":[{"id":74403,"href":"https:\/\/www.cfmot.de\/en\/wp-json\/wp\/v2\/posts\/74400\/revisions\/74403"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cfmot.de\/en\/wp-json\/wp\/v2\/media\/74396"}],"wp:attachment":[{"href":"https:\/\/www.cfmot.de\/en\/wp-json\/wp\/v2\/media?parent=74400"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cfmot.de\/en\/wp-json\/wp\/v2\/categories?post=74400"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cfmot.de\/en\/wp-json\/wp\/v2\/tags?post=74400"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}